Novel Mutations in CEBPA in Korean Patients with Acute Myeloid Leukemia with a Normal Karyotype by Kim, Sollip et al.
ISSN 2234-3806 • eISSN 2234-3814 
153 http://dx.doi.org/10.3343/alm.2012.32.2.153 www.annlabmed.org
Ann Lab Med 2012;32:153-157
http://dx.doi.org/10.3343/alm.2012.32.2.153
Brief Communication
Diagnostic Hematology
Novel Mutations in CEBPA in Korean Patients with 
Acute Myeloid Leukemia with a Normal Karyotype
Sollip Kim, M.D.
1, Dong-Hwan (Dennis) Kim, M.D.
2, Jun-Ho Jang, M.D.
2, Chul-Won Jung, M.D.
2, Mi-Ae Jang, M.D.
3, 
Chang-Seok Ki, M.D.
3, Jong-Won Kim, M.D.
3, Sun-Hee Kim, M.D.
3, and Hee-Jin Kim, M.D.
3
Department of Laboratory Medicine
1, Ilsan Paik Hospital, Inje University College of Medicine, Goyang; Departments of Medicine
2, and Laboratory Medicine & 
Genetics
3, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Mutations in the transcription factor CCAAT/enhancer binding protein α gene (CEBPA) are 
found in 5-14% of the patients with AML and have been associated with a favorable clini-
cal outcome. In this study, we aimed to assess the frequencies and characteristics of mu-
tations in CEBPA. Between 2006 and 2009, CEBPA mutations were assessed using archi-
val DNA samples obtained from 30 consecutive adult patients diagnosed with AML with a 
normal karyotype at our institution. CEBPA mutations were detected using direct sequenc-
ing analyses. These mutations were detected and described with reference to GenBank 
Accession No. NM_004364.3. In our series, CEBPA mutations were detected in 4 patients 
(13.3%). These mutations occurred as double mutations in all 4 patients. Among the 8 
mutant alleles, 5 were novel (c.179_180dupCG, c.50_53delGCCA, c.178_182delACGTinsTTT, 
c.243_244insGTCG, and c.923_924insCTC). The frequency of occurrence of CEBPA muta-
tions in Korean patients with AML is comparable to that in previous reports. Long-term fol-
low-up data from a larger series of patients with comprehensive molecular profiling are 
needed to delineate the prognostic implications.
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The karyotype at the time of diagnosis provides the most impor-
tant prognostic information in AML patients, but 40-50% of pa-
tients do not have any clonal chromosomal aberrations [1-3]. All 
such cases of AML with normal karyotype (AML-NK) are cur-
rently categorized in the intermediate-risk group; however, this 
group is quite heterogeneous [4, 5]. In recent years, many stud-
ies have shown that acquired gene mutations in AML patients 
have prognostic relevance. In particular, the fms-related tyrosine 
kinase 3 gene-internal tandem duplications (FLT3-ITD) and my-
eloid-lymphoid or mixed-lineage leukemia gene-partial tandem 
duplications (MLL-PTD) have been associated with short relapse-
free and overall survivals, whereas AML-NK with mutations in 
the nucleophosmin gene (NPM1), without concomitant FLT3-
ITD, are associated with a more favorable outcome [6]. Other 
genes that are recurrently mutated in AML include KIT, DN-
MT3A, IDH1/IDH2, and TET2. Patients with core-binding factor 
AML commonly carry activating mutations of KIT (20-45%) and 
show inferior outcomes [7]. DNMT3A mutations were detected 
in 22.1% of the AML-NK patients and were associated with ad-
verse outcomes [8]. Although IDH1 and IDH2 mutations were 
detected in 6% of AML patients and 11-12.1% of AML-NK pa-
tients, the prognostic impacts of these mutations have been 
controversial so far [9]. TET2 mutations were detected in 23% 
AML-NK patients and showed unfavorable outcomes in the fa-
vorable-risk group (AML-NK patients with mutated CEBPA and/
or mutated NPM1, without FLT3-ITD) [10]. 
  The CCAAT/enhancer binding protein α gene (CEBPA) is a 
member of the basic region leucine zipper family of transcrip-
tion factors. It is an intronless gene located on chromosome 
19q13.1. It is composed of 2 transactivation domains in the N-
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terminal region—a basic leucine zipper region (bZIP) that medi-
ates dimerization with other CEBP family members and a DNA-
binding domain in the C-terminal region [11]. The importance of 
CEBPA in hematopoiesis can be attributed to its crucial role 
during the development of granulocytes and its deregulation as-
sociated with myeloid transformation [11]. Mutations in CEBPA 
are found in 5-14% of AML patients and have been associated 
with a favorable clinical outcome [12]. Most CEBPA mutant AML 
patients simultaneously exhibit 2 mutations (CEBPAdouble-mut), 
which most frequently involve a combination of an N-terminal 
frame-shift mutation and a C-terminal insertion mutation, that 
are usually biallelic [12]. In a recent study involving a large co-
hort of AML-NK patients, only CEBPAdouble-mut was associ-
ated with a unique gene expression profile and favorable overall 
and event-free survivals on multivariate analyses including fac-
tors such as age, white blood cell count, cytogenetic informa-
tion, and FLT3-ITD and NPM1 mutation status. Therefore, CEB-
PAdouble-mut was considered a separate disease entity in the 
classification of AML [13-15]. 
  In this study, we aimed to assess the frequencies and charac-
teristics of CEBPA mutations in Korean patients with AML-NK. 
Between 2006 and 2009, CEBPA mutations were assessed in 30 
consecutive adult patients diagnosed with AML-NK at our insti-
tution. Of these patients, 18 were men and 12 women, with a 
median age of 53 yr (range, 24-88 yr) at diagnosis. According to 
the WHO classification [16], 13 patients were diagnosed with 
AML with myelodysplasia-related changes, 8 with AML with mat-
uration, 3 with AML without maturation, 3 with acute monoblas-
tic/monocytic leukemia, and 1 each with AML with minimal dif-
ferentiation, acute myelomonocytic leukemia, and acute ery-
throid leukemia. The patients were shown to have no recurrent 
molecular abnormalities on multiplex reverse-transcriptase PCR 
using the Hemavision-Full Kit (DNA technology A/S, Aarhus C, 
Denmark) and a panel of FISH assays (LSI p53 on 17p13.1, LSI 
D20S108 on 20q12, LSI D7S522 on 7q31/CEP 7, CEP 8, LSI EGR1 
on 5q31/D5S23, D5S721 on 5p15.2, and LSI MLL dual color, LSI 
CBFB dual color, or LSI RUNX1/RUNX1T1 on 8q22/21q22 probes 
[Abbott Molecular/Vysis, Des Plaines, IL, USA]). All patients, ex-
cept 3 who had refused treatment, received conventional induc-
tion chemotherapy with idarubicin and cytosine arabinoside. 
Data about complete blood counts and the proportion of blasts 
on peripheral blood (PB) and bone marrow (BM)-aspiration 
smear were obtained by reviewing electronic medical records. 
We also reviewed the data on immunophenotyping obtained by 
flow cytometry; FLT3/ITD, FLT3/TKD, and NPM1 mutations; and 
clinical outcomes after induction chemotherapy.
  Genomic DNA extracted from the BM aspirates was analyzed 
using the Wizard Genomic DNA Purification Kit (Promega, Madi-
son, WI, USA) according to the manufacturer’s instructions. 
Written informed consent was obtained from the patients. The 
study protocol was approved by the Institutional Review Board of 
our institution. The coding sequences and flanking intronic re-
gions of the CEBPA genes were amplified using the previously 
described primer sets [13, 17]. PCR was performed using a ther-
mal cycler (model 9700; Applied Biosystems, Foster City, CA, 
USA). Cycle sequencing was performed using the ABI Prism 
3100 Genetic Analyzer and the BigDye Terminator Cycle Se-
quencing Reaction Kit (Applied Biosystems). When variations 
were observed in the sequences obtained using these methods 
and the reference sequences, we performed follow-up tests by 
using BM or PB specimens collected at complete remission; 2 
PB specimens from healthy volunteers and 2 BM specimens 
showing no involvement of lymphoma during staging workup 
were used as controls. CEBPA mutations were described accord-
ing to the guidelines of the Human Genome Variation Society by 
using the reference sequences NM_004364.3 and NP_ 004355.2. 
Only an insertion polymorphism or variation(s) not leading to 
amino acid changes was considered wild type [13, 18, 19].
  In our study, CEBPA mutations were detected in 4 patients 
(13.3%), and all had double mutations (Fig. 1). CEBPA double 
mutations in these 4 patients were c.179_180dupCG at the N-
terminal region [N] and c.929_930insTCT at the C-terminal re-
gion [C]; c.50_53delGCCA [N] and c.912_913insTTG [C]; c.178_ 
182delACGTinsTTT [N] and c.923_924insCTC [C]; and c.243_ 
244insGTCG [N] and c.912_913insTTG [C]. Among these muta-
tions, c.179_180dupCG, c.50_53delGCCA, c.178_182delACGTins 
TTT, c.243_244insGTCG, and c.923_924insCTC were novel mu-
tations. All patients (4/4, 100%) with CEBPA mutations showed a 
CR after induction chemotherapy, whereas 84.6% (22/26) of pa-
tients without CEBPA mutations showed a CR after induction 
chemotherapy. The CEBPA mutations were not observed in the 
follow-up samples at complete remission. FLT3-ITD was detected 
in 10% (3/30) of the patients, and the NPM1 mutation in 37.5% 
(9/24). Among the 4 patients with CEBPAdouble-mut, 1 also had 
the FLT3-ITD mutation, whereas none of them had the NPM1 
mutation. Detailed clinical and molecular characteristics of these 
4 patients are shown in Table 1. Six-nucleotide in-frame insertion 
polymorphisms of CEBPA were observed in 30% (9/30) of the 
patients. This polymorphism was also observed in the follow-up 
samples at complete remission and in control BM specimens. 
  Our results showed that the frequency of CEBPA mutations in 
Korean patients with AML-NK is 13.3% (4/30), which is compa-Kim S, et al.
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rable to the frequency reported in previous studies on other eth-
nic groups [20-24]. All 4 patients showed double mutations (one 
each in the N- and C-terminal regions). We also found 5 novel 
mutations: c.179_180dupCG [p.S61Afs], c.50_53delGCCA [p. 
H18Qfs], c.178_182delACGTinsTTT [T60Ffs], c.243_244insGTCG 
[p.F82Vfs], and c.923_924insCTC [p.K304_Q305insL]. Moreover, 
Fig. 1. CEBPA mutations detected in 4 patients.
CEBPA mutations occurred as double mutations in all 4 patients. CEBPA double mutations in these patients were c.179_180dupCG [N] and 
c.929_930insTCT [C], c.50_53delGCCA [N] and c.912_913insTTG [C], c.178_182delACGTinsTTT [N] and c.923_924insCTC [C], and 
c.243_244insGTCG [N] and c.912_ 913insTTG [C]. Among these mutations, c.179_180dupCG, c.50_53delGCCA, c.178_182delACGTinsTTT, 
c.243_244insGTCG, and c.923_924insCTC were novel mutations.
A
C
B
D
Case 1
  TAD1: c.179_180dupCG
Foward Foward
Foward Foward
Foward Foward
Foward Foward
Reverse Reverse
Reverse Reverse
  bZIP: c.929_930insTCT   bZIP: c.912_913insTTG
  bZIP: c.923_924insCTC   bZIP: c.912_913insTTG
Reverse Reverse
Reverse Reverse
Case 3
  TAD1: c.178_182delACGTCinsTTT
Case 4
  TAD1: c.243_244insGTCG
Case 2
  TAD1: c.50_53delGCCA
Table 1. Clinical and molecular characteristics of 4 Korean patients with AML-NK harboring CEBPA double mutations
Patient
No.
Age (yr)/ 
Sex BM diagnosis Immunophenotype
CEBPA gene mutation*
FLT3/ITD NPM1
N-terminal C-terminal
1 51/F
AML with 
MRC
CD34
+, HLA-DR
+, CD13
+, CD33
+, CD117
+, 
cMPO
+, CD64
+, ectopic CD7
+
c.179_180dupCG
(p.S61Afs)
c.929_930insTCT 
(p.310_311insL)
Neg Neg
2 41/F
AML with 
maturation
CD34
+, HLA-DR
+, CD13
+, CD33
+, CD117
+, 
MPO
+, CD64w
+, ectopic CD7
+
c.50_53delGCCA
(p.H18Qfs)
c.912_913insTTG
(p.K304_Q305insL)
Pos Neg
3 48/F
AML with 
maturation
CD34
+, HLA-DR
+, CD13
+, CD33
+, CD117
+, 
MPO
+, CD64
+, ectopic CD7w
+
c.178_182delACGTinsTTT
(T60Ffs)
c.923_924insCTC
(p.K304_Q305insL)
Neg Neg
4 42/F
AML with 
maturation
CD34
+, HLA
-DR
+, CD13
+, CD33
+, CD117
+, 
MPO
+, CD64w
+, ectopic CD7
+
c.243_244insGTCG
(p.F82Vfs)
c.912_913insTTG
(p.K304_Q305insL)
Neg Neg
*Description at the cDNA level (reference sequence: NM_004364.3) and that at the protein level (NP_004355.2) in parentheses, according to the guidelines 
of the Human Genome Variation Society.
Novel mutations are in bold.
Abbreviations: AML, acute myeloid leukemia; NK, normal karyotype; BM, bone marrow; ITD, internal tandem duplication mutations; MRC, multilineage-relat-
ed dysplasia; Neg, negative; Pos, positive.Kim S, et al.
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we also confirmed the disappearance of CEBPAdouble-mut in 
the follow-up samples at complete remission (leukemia-specific 
genetic changes). N-terminal mutations are located between 
the major translational start codon and the second ATG in the 
same open reading frame [13]. These mutations introduce a 
premature termination of translation of the p42 CEBPA protein, 
while preserving the translation of a p30 isoform that has been 
reported to inhibit the function of the full-length protein. In con-
trast, mutations in the C-terminal bZIP region are in-frame mu-
tations, and they may impair DNA binding and/or homodimer-
ization and heterodimerization [13].
  We found that c.584_589dupACCCGC (9/30, 30%) and c. 
690G>T (2/30, 6.7%) were the most common types of CEBPA 
polymorphisms. Although c.584_589dupACCCGC was first re-
ported as a mutation [25], this 6-nucleotide in-frame duplication 
has recently been shown to represent a germline polymorphism 
(P194_H195dup) [18, 26, 27]. We detected this variation in the 
follow-up samples of patients at CR and in control samples. 
  Of the 4 patients with CEBPAdouble-mut, 1 also had the 
FLT3-ITD mutation, whereas none of them had the NPM1 mu-
tation. Acquired gene mutations in AML fall into either of the 2 
broadly defined complementation groups (Class I and II) [1]. 
Class I comprises mutations that activate signal-transduction 
pathways and thereby increase the proliferation or survival, or 
both, of hematopoietic progenitor cells [1]. Mutations that acti-
vate members of the receptor tyrosine kinase FLT3 or RAS fami-
lies are considered Class I mutations. Class II comprises muta-
tions that affect transcription factors or components of the tran-
scriptional coactivator complex and cause impaired differentia-
tion. On the basis of their known physiological functions, muta-
tions in CEBPA, MLL, and possibly NPM fall into this group [6]. 
A recent study that comprehensively analyzed gene mutations in 
AML showed that 103 of 165 patients had multiple gene muta-
tions, which most frequently occurred as a combination of Class 
I and Class II mutations [20]. In addition to gene mutations, hy-
permethylation of the distal promoter region of CEBPA has been 
reported to have a prognostic implication in a significant propor-
tion of AML patients [28, 29]. Notably, hypermethylation and 
gene mutation were mutually exclusive in AML [28]. These evi-
dences suggest that methylation testing may be needed along 
with gene mutation studies to detect CEBPA mutations in AML.
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